Sign In
Buy MLYS
$25.61
+0.240 (+0.95%)
At Close: Jun 23, 2026
Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference
04:05pm, Monday, 29'th Jan 2024
RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic k
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Wednesday, 17'th Jan 2024
Mineralys Therapeutics, Inc. (MLYS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
04:05pm, Thursday, 04'th Jan 2024
RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic k
– Topline data from confirmatory Launch-HTN trial expected in 2H 2025 – – Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024 – RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE)
Mineralys Therapeutics Inc. (MLYS) Q3 2023 Earnings Call Transcript
12:06am, Sunday, 12'th Nov 2023
Mineralys Therapeutics Inc. (NASDAQ:MLYS ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam L
– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone –
Mineralys Therapeutics to Participate in Three Upcoming Conferences
04:05pm, Thursday, 09'th Nov 2023
RADNOR, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic k
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 07'th Nov 2023
– On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat to treat patients with uncontrolled or resistant hypertension in 2H 2023 –
– Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant
Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on Tuesday, November 7, 2023
04:05pm, Tuesday, 31'st Oct 2023
RADNOR, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic k
Mineralys Therapeutics to Participate in the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 28, 2023
04:05pm, Monday, 11'th Sep 2023
RADNOR, Pa., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic
Wall Street Analysts See a 199.3% Upside in Mineralys Therapeutics, Inc. (MLYS): Can the Stock Really Move This High?
11:17am, Tuesday, 05'th Sep 2023
The mean of analysts' price targets for Mineralys Therapeutics, Inc. (MLYS) points to a 199.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ag
Mineralys Therapeutics, Inc. (MLYS) Loses -19.64% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
06:47pm, Tuesday, 22'nd Aug 2023
Mineralys Therapeutics, Inc. (MLYS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising
Mineralys Therapeutics, Inc. (MLYS) Q2 2023 Earnings Call Transcript
01:15pm, Saturday, 12'th Aug 2023
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q2 2023 Results Conference Call August 7, 2023 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Lev
Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results and Host Conference Call on Monday, August 7, 2023
04:05pm, Monday, 31'st Jul 2023
RADNOR, Pa., July 31, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abno
